Phio Pharmaceuticals Announces Dosing Of First Patient in Collaborative Clinical Trial With AgonOx, Inc. And Providence Cancer Institute
Portfolio Pulse from Benzinga Newsdesk
Phio Pharmaceuticals has announced the dosing of the first patient in a collaborative clinical trial with AgonOx, Inc. and Providence Cancer Institute.
August 21, 2023 | 11:33 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Phio Pharmaceuticals has started dosing in a collaborative clinical trial, which could potentially lead to advancements in their product offerings and partnerships.
The commencement of dosing in a new clinical trial indicates progress in Phio Pharmaceuticals' research and development efforts. This could potentially lead to new product offerings and strengthen their partnerships, which could positively impact their stock price in the short term.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100